🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting over 82 million infections each year. Notably increased rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, the spread of superbugs and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance found that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers hope that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in concurrent days. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Data and Global Access

As per results detailed in a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which uses two antibiotics. The trial enrolled nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the rights to license and sell the drug in many low-income and middle-income countries.

Doctors on the front lines have shared hope. The availability of a one-pill regimen like this is seen as a "game-changer" for public health efforts. This is viewed as vital to lessen the impact of the infection for people and to stop the proliferation of untreatable gonorrhoea globally.